1
|
Luhata Lungayo C, Burke RM, Cikomola A, Mukamba E, Burnett E, Tate JE, Samuel Otomba J, Albert MK, Nimpa MM, Dommergues MA, Pukuta E, Mwenda JM, Shaba K, Paluku GK, N'diaye A, Ditekemena J, Launay O, Jouffroy R. Epidemiology and pre-vaccine burden of rotavirus diarrhea in Democratic Republic of Congo (DRC): Results of sentinel surveillance, 2009-2019. Vaccine 2022; 40:5933-5941. [PMID: 36068112 PMCID: PMC11494495 DOI: 10.1016/j.vaccine.2022.08.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Revised: 08/16/2022] [Accepted: 08/17/2022] [Indexed: 11/20/2022]
Abstract
INTRODUCTION Since August 2009, the Democratic Republic of Congo (DRC) has implemented sentinel site surveillance for rotavirus gastroenteritis. Limited hospital studies have been carried out, in DRC, describing the epidemiology of rotavirus diarrhea before rotavirus vaccine introduction in October 2019. This analysis describes the epidemiology of rotavirus gastroenteritis and characteristics of circulating viral strains from 2009 to 2019. MATERIALS AND METHODS We analyzed demographic and clinic data collected from children < 5 years old enrolled at three rotavirus sentinel surveillance sites in DRC during 2009-2019, prior to rotavirus vaccine introduction in 2019. Data have been described and presented as mean ± standard deviation for quantitative variables with normal distribution, or as median with an interquartile range [Q1-Q3] for quantitative variables with non-normal distribution, or as absolute value with percentage for qualitative variables. RESULTS Between August 2009 and December 2019, 4,928 children < 5 years old were admitted to sentinel surveillance sites for gastroenteritis in the DRC; the rotavirus positivity rate was 60 %. There was a slight male gender predominance (56 %), and the majority of children (79 %) were 0-11 months of age. Every year, the incidence was highest between May and September corresponding to the dry and cool season. Genotyping was performed for 50 % of confirmed rotavirus cases. The most common G genotypes were G1 (39 %) and G2 (24 %) and most common P genotypes were P[6] (49 %) and P[8] (37 %). The most common G-P genotype combinations were G1P[8] (22 %), G2P[6] (16 %) and G1P[6] (14 %). Genotype distribution varied by site, age group, and year. CONCLUSION From 2009 to 2019, rotavirus-associated gastroenteritis represented a significant burden among DRC children under 5 who were admitted to sentinel sites. G1P[8] was the most commonly identified genotype. Continued monitoring after the introduction of rotavirus vaccine will be essential to monitor any changes in epidemiology.
Collapse
Affiliation(s)
- Christophe Luhata Lungayo
- Expanded Program of Immunization, Kinshasa, Democratic Republic of Congo; INSERM U-1018, Centre de recherche en Epidémiologie et Santé des Populations (CESP) - U1018 INSERM, Université Paris Saclay, Paris, France.
| | - Rachel M Burke
- Viral Gastroenteritis Branch, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Aimé Cikomola
- Expanded Program of Immunization, Kinshasa, Democratic Republic of Congo
| | - Elisabeth Mukamba
- Expanded Program of Immunization, Kinshasa, Democratic Republic of Congo
| | - Eleanor Burnett
- Viral Gastroenteritis Branch, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Jacqueline E Tate
- Viral Gastroenteritis Branch, Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | - Mbule K Albert
- World Health Organization Country Office, Democratic Republic of Congo
| | - Marcellin M Nimpa
- World Health Organization Country Office, Democratic Republic of Congo
| | - M A Dommergues
- Service de pédiatrie générale, centre hospitalier de Versailles, Le Chesnay, France
| | - Elisabeth Pukuta
- Institut National de Recherches Biomédicales (I.N.R.B), République Démocratique du Congo
| | - Jason M Mwenda
- Regional Office for Africa, World Health Organization, Brazzaville, Congo
| | - Keith Shaba
- Regional Office for Africa, World Health Organization, Brazzaville, Congo
| | - Gilson K Paluku
- World Health Organization, Intercountry Support Team, Libreville, Gabon
| | - Aboubacar N'diaye
- World Health Organization, Intercountry Support Team, Libreville, Gabon
| | - John Ditekemena
- Kinshasa School of Public Health, Faculty of Medicine, University of Kinshasa, Democratic Republic of Congo
| | - Odile Launay
- Université Paris Descartes, Sorbonne Paris cite, and Inserm CIC 1417, F-CRIN I-Reivac, Assistance Publique Hôpitaux de Paris, CIC Cochin-Pasteur, Paris, France
| | - Romain Jouffroy
- INSERM U-1018, Centre de recherche en Epidémiologie et Santé des Populations (CESP) - U1018 INSERM, Université Paris Saclay, Paris, France; Intensive Care Unit, Ambroise Paré Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France; IRMES - Institute for Research in Medicine and Epidemiology of Sport, INSEP, Paris, France; EA 7329, Université de Paris, Paris, France; EA 7525 Université des Antilles, Pointe-Pitre, France
| |
Collapse
|
2
|
Mwenda JM, Parashar UD, Cohen AL, Tate JE. Impact of rotavirus vaccines in Sub-Saharan African countries. Vaccine 2018; 36:7119-7123. [PMID: 29914848 PMCID: PMC11726318 DOI: 10.1016/j.vaccine.2018.06.026] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2018] [Revised: 04/25/2018] [Accepted: 06/11/2018] [Indexed: 10/28/2022]
Abstract
By the end of 2017, 32 (68%) of 47 countries in the World Health Organization's African Region had introduced rotavirus vaccine into their national immunization programs, including 27 countries that received financial support from the Gavi, the Vaccine Alliance. Several early introducing African countries previously evaluated the impact, vaccine effectiveness, and/or cost effectiveness of their routine rotavirus vaccination programs and found that rotavirus vaccine was effective and resulted in substantial declines in hospitalizations due to rotavirus. This Special Issue of Vaccine provides additional rotavirus vaccine effectiveness and impact data from a broader range of African countries, describes the longer term impact and potential indirect benefits of rotavirus vaccination programs, describes trends in circulating genotypes in the pre- and post-vaccine introduction eras, and evaluates the cost-effectiveness of a rotavirus vaccination program in a post-introduction setting. As countries begin transitioning from Gavi support, the findings of these studies provide evidence of the impact and effectiveness of rotavirus vaccination programs under conditions of routine use.
Collapse
Affiliation(s)
- Jason M Mwenda
- World Health Organization Regional Office for Africa, (WHO/AFRO), Brazzaville, Congo
| | | | | | | |
Collapse
|